Allergy Therapeutics plc (AGY.L) issued a trading update for the year ended 30 June 2024. Revenue for the year ended 30 June 2024 is expected to be 7% lower at 55.2 million pounds from 59.6 million pounds, last year. Revenue for second half is expected to have increased by 2% to 21.6 million pounds from 21.2 million pounds, prior year.
The Group stated that financial turnaround is progressing with expected revenue growth in the second half, marking the first period of half year growth since 2021. The unaudited cash balance at 30 June 2024 was 12.9 million pounds.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.